DRREDDY
Dr. Reddy’s Laboratories Limited Q2fy27 Results Update: Double-digit Growth, Strong Financials
Dr. Reddy’s Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.
Financial Highlights
The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.
Strategic Initiatives
Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.
The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (NSE: Drreddy) Receives DCGI Approval for Zytorvi® in Advanced Esophageal Squamous Cell Carcinoma
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced DCGI approval for Zytorvi® in advanced esophageal squamous cell carcinoma.
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).
Expanding Access to Immunotherapy
Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.
Significant Market Opportunity
In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (drreddy) Q2fy27 Results: Earnings and Revenue Insights
Dr. Reddy’s Laboratories Limited (DRREDDY) to announce Q2FY27 results on October 23rd, focusing on earnings and revenue insights.
Dr. Reddy’s Laboratories Limited (DRREDDY) is set to release its financial results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd. The announcement will focus on key earnings and revenue insights. The company will hold an earnings call at 19:30 PM IST / 10:00 AM ET to discuss the financial performance. The call will be hosted by the company and can be accessed via the provided link for registration. This event marks a significant moment for investors and stakeholders to gain a deeper understanding of the company’s financial health and future prospects.
Financial Performance Overview
The upcoming release will provide detailed insights into Dr. Reddy’s Laboratories’ financial performance for Q2FY27. Notably, the company’s earnings and revenue are expected to reflect its strategic initiatives and market dynamics. The earnings call will offer a platform for management to elaborate on these aspects, highlighting key metrics and future growth strategies.
Investor Engagement
Investors are encouraged to participate in the earnings call to gain direct insights from the company’s leadership. The call will be available in audio format, with a transcript also accessible on the company’s website. This engagement is crucial for understanding the company’s current standing and future trajectory in the pharmaceutical sector.
As Dr. Reddy’s Laboratories Limited prepares to unveil its Q2FY27 results, the focus remains on delivering valuable financial insights that will guide stakeholders in making informed decisions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. falls 10.4% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -10.4% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) receives FDA approval for its rituximab biosimilar, expanding its global biosimilars portfolio.
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) today announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar, a biosimilar to Rituxan® (rituximab), for the U.S. market. This approval further strengthens Dr. Reddy’s growing global biosimilars portfolio and advances its biosimilars business in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy’s Laboratories. The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company’s biologics manufacturing facility in Bachupally, Hyderabad.
Strengthening Global Biosimilars Portfolio
The FDA approval is a significant milestone for Dr. Reddy’s Laboratories. The rituximab biosimilar has been commercialized in India, the European Union, the United Kingdom, and more than 25 emerging markets, and has also received marketing approval in Switzerland and Canada. This latest approval marks a major step in the company’s strategy to expand its biosimilars business in the U.S., one of the world’s most important pharmaceutical markets.
Commercialization Agreement with Fresenius Kabi
Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States. This partnership will leverage Fresenius Kabi’s expertise and market reach to maximize the product’s availability and impact in the U.S. market.
As Dr. Reddy’s Laboratories continues to invest in its biosimilars business, this approval underscores the company’s capabilities in developing and manufacturing complex biologic medicines for global markets. The biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency, consistent with FDA requirements for biosimilar approval.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. falls 13.2% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 11.0% CAGR — a respectable pace. However, the stock drops 13.2% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
-
AYE2 days agoAye Finance Limited (NSE: AYE) Q2fy27: Highest-ever Quarterly Profit of INR 87 Crore
-
FSL3 days agoFirstsource Solutions Limited (FSL) Named Horizon 3 Market Leader in HFS Horizons: Customer Experience Services, 2026
-
Healthcare2 days agoNureca Limited (nureca) Q2 FY27: Revenue Up 55%, Records Highest Quarterly Revenue in Last 20 Quarters
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Partners with Prolific Machines to Scale Biologics Manufacturing
-
Basic Materials2 days agoInternational Gemological Institute Limited (igil) Q2 FY27: Certification Revenue Up 32%, Ebitda Growth at 39%
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Receives USFDA Approval for Estradiol and Levonorgestrel
-
INFOBEAN2 days agoInfobeans Technologies Limited (infobean) Achieves Select Partner Tier in the Claude Partner Network Services
-
Information Technology Services2 days agoLtm Limited (LTM) Launches Blueverse™ Valuemesh™ to Help Enterprises Scale AI Across Oracle